Summary & Overview
HCPCS Level II J9270: Injection, Plicamycin 2.5 mg
HCPCS Level II code J9270 denotes the injection of plicamycin in a 2.5 mg unit. This drug-specific billing code is relevant for facilities and clinicians that administer parenteral oncologic or hematologic therapies, and it plays a role in drug utilization tracking, payer coverage decisions, and facility charge capture nationally. Key payers considered in standard analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of what J9270 represents clinically and operationally, a summary of payer coverage patterns, and the typical sites of service where the injection is provided. The publication also outlines benchmarks commonly used in billing reviews, identifies policy and reimbursement considerations affecting access and billing for single-dose specialty injections, and provides clinical context for when plicamycin might be used. If specific data elements (such as associated taxonomies, ICD-10 diagnoses, or related procedure lines) are not available in the input, the text notes that those items are not provided.
Billing Code Overview
HCPCS Level II code J9270 describes the injection of plicamycin, supplied in 2.5 mg units. This code represents a single dose drug administration for plicamycin, a medication used in select oncologic and hematologic settings.
-
Service type: Injectable drug administration
-
Typical site of service: Hospital outpatient department, clinic, or physician office where parenteral chemotherapy or specialty injections are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a diagnosis requiring cytotoxic therapy or biochemical modulation for a neoplastic process, such as metastatic testicular tumor or selected childhood tumors, for which plicamycin (J9270) is prescribed as an antineoplastic agent. The clinical workflow begins with oncology evaluation and documented indication. Baseline labs (CBC, renal and hepatic panels, coagulation studies, and electrolytes) are obtained to confirm candidacy. The infusion nurse or oncologist verifies dose (multiples of 2.5 mg per J9270 unit), prepares the medication in a controlled pharmacy environment, and administers intravenous injection or short infusion in an oncology infusion suite, hospital outpatient department, or inpatient ward depending on intensity of monitoring required. Patient is monitored for infusion reactions, hemorrhagic risk, hypocalcemia, and organ toxicity during and after administration; repeat laboratory monitoring and documentation of drug lot, dose, route, date, and time are completed in the medical record. Billing uses J9270 per 2.5 mg unit; appropriate diagnosis code(s) for the treated malignancy are linked on the claim, and applicable modifier(s) are appended when clinical circumstances (e.g., professional component, unusual services, or reduced services) require clarification.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|